Sep. 9 at 1:29 PM
$DWTX The company’s narrative revolves around its pain and fatigue management pipeline: [1]
Halneuron Phase 2b Trial: "The company's lead product candidate is Halneuron, which is in Phase 2b development to treat pain conditions, including the neuropathic pain associated with chemotherapy treatment." The trial has enrolled 217 patients, and top-line data in late 2026 represents the ultimate make-or-break event for the firm. [1, 2]
SP16 Progression: This secondary asset recently received FDA Investigational New Drug (IND) clearance. Fully funded by the National Cancer Institute, it targets chemotherapy-induced pain and peripheral neuropathy. [1]
